0
Détail de l'indexation
TA 6.2.3.1.4 : Autres substituts nicotiniques |
Ouvrages de la bibliothèque en indexation TA 6.2.3.1.4 (43)
Ajouter le résultat dans votre panier Affiner la recherche
To smoke or not to smoke ? / Jean-Charles Delespaux (29/06/2007)
Titre : To smoke or not to smoke ? Type de document : texte imprimé Auteurs : Jean-Charles Delespaux, Auteur Editeur : Bruxelles : Actuamedica Année de publication : 29/06/2007 Collection : Le Journal du Médecin num. 1848 Importance : p.8-9 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Une société belge vient de commercialiser une 'cigarette plus saine'. elle en vante l'absence de risque sur le plan carcinologique et promet de satisfaire les amateurs de tabac. Aurait-on enfin trouvé une parade efficace et hédonique au fléau mondial que représente le tabagisme ? Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2383 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001397 TA 6.2.3.1.4 DEL T Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Tobacco smoking cessation management : integrating varenicline in current practice Type de document : texte imprimé Auteurs : Laurence Galanti, Auteur Editeur : Dove Medical Press Année de publication : 2008 Collection : Vascular health and risk management, ISSN 1176-6344 num. Vol. 4, n. 4 Importance : p. 837-845 Présentation : tab. Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Tobacco smoking is widespread and is one of the world’s most prevalent modifiable risk factors for morbidity and mortality. It is important to facilitate smoking cessation better in order to reduce the health consequences of tobacco use. The most effective approach assisting smokers in their quit attempts combines both pharmacotherapy and nonpharmacological interventions. This review summarizes the latest international epidemiological data available on tobacco use, considers the associated effects on health, and reviews existing policies against tobacco use. Among the interventions for smoking cessation, the three major pharmacotherapies (which have demonstrated efficacy when combined with behavioral support) are discussed: nicotine replacement therapy (NRT), bupropion, and varenicline. As the newest pharmacotherapy made available in this area, particular consideration is given to varenicline, and a review of our clinical experience is offered. En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597768/ Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7953 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline, an alpha-4-beta-2(α4β2) nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation / David H. Gonzales (01/06/2006)
Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline and bupropion sustained-release combination therapy for smoking cessation / Jon O. Ebbert (2009)
Titre : Varenicline and bupropion sustained-release combination therapy for smoking cessation Type de document : texte imprimé Auteurs : Jon O. Ebbert, Auteur ; Ivana T. Croghan, Auteur ; Amit Sood, Auteur Editeur : Oxford University Press Année de publication : 2009 Collection : Nicotine and Tobacco Research num. Vol 11, n.3 Importance : p. 234-239 Présentation : tad., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract
INTRODUCTION:
Varenicline and bupropion sustained release (SR) are both safe and effective for the treatment of tobacco dependence and have different mechanisms of action. Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy.
METHODS:
We enrolled cigarettes smokers in an open-label, one-arm, Phase II clinical trial to obtain preliminary data on the potential effectiveness and safety of combination therapy with varenicline and bupropion SR for the treatment of tobacco dependence. Eligible subjects received varenicline titrated to 1.0 mg by mouth twice daily and bupropion SR titrated to 150 mg by mouth twice daily for a total of 12 weeks along with behavioral therapy. Self-reported smoking abstinence was biochemically confirmed with expired carbon monoxide. A total of 38 smokers with a mean age of 49.1 years (SD = 12.4) who smoked an average of 19.9 cigarettes/day (SD = 7.8) for 30 years (SD = 12.3) were enrolled.
RESULTS:
Seven-day point-prevalent smoking abstinence rates were 71% (95% CI = 54%-85%) at 3 months and 58% (95% CI = 41%-74%) at 6 months. Mean weight change during the medication phase among smoking-abstinent subjects was 1.6 kg (SD = 2.4). For both medications, 74% of subjects took at least 90% of the prescribed doses. The most common side effects were sleep disturbance (26%) and nausea (24%). No increase in depressive symptoms was observed, and no subjects reported suicidal ideation.
DISCUSSION:
Combination therapy with varenicline and bupropion SR may be effective for increasing smoking abstinence rates above that observed with monotherapy.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7947 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005488 TA 6.2.3.1.4 EBB V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline for smoking cessation (2008)
Titre : Varenicline for smoking cessation Type de document : texte imprimé Editeur : BMJ Publishing Group Année de publication : 2008 Collection : Drug and therapeutics bulletin, ISSN 0012-6543 num. Vol 46, n.5 Importance : p. 33-36 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Varenicline (pronounced va-re-nik-leen) (Champix – Pfizer), a nicotinic receptor partial agonist, is the first medicine of this type licensed for smoking cessation in adults. Launched in the UK in December 2006, the drug accounted for 14% of all prescription items and 22% of total expenditure, for smoking cessation products dispensed in the community in 2007*.1–4 Marketing materials claim that it has a “unique dual action”, a “significantly higher quit rate” than bupropion, and a “favourable safety and tolerability profile”. Here we discuss the evidence for varenicline and consider its role in smoking cessation. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7941 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005482 TA 6.2.3.1.4 VAR V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline for smoking cessation / Robert C. Klesges (2006)
Titre : Varenicline for smoking cessation : definite promise, but no panacea Type de document : texte imprimé Auteurs : Robert C. Klesges, Auteur ; Karen C. Johnson, Auteur ; Grant Somes, Auteur Editeur : American Medical Association (AMA) Année de publication : 2006 Collection : JAMA Internal Medicine num. Vol 296, n. 1 Importance : p. 94-95 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7943 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005484 TA 6.2.3.1.4 KLE V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Varenicline for smoking cessation : is it a heartbreaker? Type de document : texte imprimé Auteurs : J. Taylor Hays, Auteur Editeur : Canadian medical association Année de publication : 2011 Collection : Canadian medical association journal, ISSN 0008-4409 Importance : 2 p. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:pathologie:pathologie cardio-vasculaireIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Risk of serious adverse cardiovascular events associated wirh varenicline a systematic review and meta-analysis En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168613/ Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7949 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Varenicline for tobacco dependence Type de document : texte imprimé Auteurs : J. Taylor Hays, Auteur ; Jon O. Ebbert, Auteur Editeur : Massachusetts Medical Society Année de publication : 2008 Collection : New England Journal of Medicine num. Vol 259 Importance : p. 2018-2024 Présentation : ill., tab. Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959114/ Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7952 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline (2006)
Titre : Varenicline : guidance for health professionals on a new prescription-only stop smoking medication Type de document : texte imprimé Editeur : Action on smoking and health (ASH) Année de publication : 2006 Présentation : tab., ill. Langues : Anglais (eng) Catégories : [DIVERS] personne:par métier:professionnel de la santé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Varenicline, which will be called Champix in the UK, is due to be launched on prescription in
early December 2006. We are publishing this guidance to help smoking cessation advisers
and other health professionals decide how to manage anticipated demand for this new stop
smoking medication. In this paper we briefly describe varenicline, review the evidence that it
works, and make recommendations on how to use it, based on the research evidence, the
SPC (Summary of Product Characteristics), and expert opinion.
The National Institute for Health and Clinical Excellence (NICE) will be issuing their guidance
on varenicline around the late spring or early summer of 2007, and therefore this document
gives interim guidance only. Furthermore, because varenicline is a new, centrally acting
drug, with limited time yet for adverse effects to emerge, we have not made a
recommendation as to whether it should be a first or second line smoking cessation
treatment. We think this judgment should be made by the prescribing physician in
consultation with the smoker, following a discussion of efficacy and safety profiles of
available treatments, contraindications and precautions, and taking into account patient
preference and experience of other treatments. When the NICE guidance is published there
will be more experience of the drug, including of adverse events.
Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7971 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005511 TA 6.2.3.1.4 VAR V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline has antidepressant-like in activity in the forced swim test augments sertraline's effect / Hans Rollema (2009)
Titre : Varenicline has antidepressant-like in activity in the forced swim test augments sertraline's effect Type de document : texte imprimé Auteurs : Hans Rollema, Auteur ; Victor Guanowsky, Auteur ; Yann S. Mineur, Auteur Editeur : Elsevier Science Direct Année de publication : 2009 Collection : European Journal of Pharmacology, ISSN 0014-2999 num. Vol 605 Importance : p. 114-116 Présentation : graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist developed as a smoking cessation aid, showed antidepressant-like activity in the forced swim test in two mouse strains. In addition, a low varenicline dose significantly enhanced the effects of moderately active doses of the selective serotonin reuptake inhibitor sertraline. These findings are consistent with the notion that reducing alpha4beta2 nicotinic acetylcholine receptor activity either by antagonists or by partial agonists that can partially activate or desensitize acetylcholine receptors is associated with antidepressant-like properties. These data suggest that varenicline may have antidepressant potential and can, when combined, augment antidepressant responses of selective serotonin reuptake inhibitors. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7946 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005487 TA 6.2.3.1.4 ROL V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Varenicline : new treatment with efficacy in smoking cessation Type de document : texte imprimé Auteurs : Victor I. Reus, Auteur ; R. Scott Obach, Auteur ; Jotham W. Coe, Auteur ; Helene Faessel, Auteur ; Hans Rollema, Auteur ; Eric Watsky, Auteur ; Karen Reeves, Auteur Editeur : Barcelona [Espagne] : Thomson Reuters Année de publication : 2007 Collection : Drugs of today, ISSN 1699-3993 num. 43(2) Importance : p.65-75 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique
[TABAC] sevrage tabagique:efficacité du sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Smoking is a significant public health problem, and existing treatments have demonstrated only moderate efficacy in assisting smokers to quit. Varenicline, recently approved by the U.S. Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products as an aid to smoking cessation treatment, has a novel mechanism of action, targeting the specific nicotinic acetylcholine receptor (nAChR) associated with nicotine-induced behaviors (alpha4beta2 nAChR). It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking. The clinical efficacy and tolerability of varenicline has been demonstrated in phase III clinical trials involving more than 2,000 cigarette smokers. At the end of the treatment period in two 12-week, multicenter, randomized, double-blind, placebo-controlled studies, patients receiving varenicline (1 mg twice daily) experienced an increase in the odds of quitting smoking by nearly fourfold compared with those receiving placebo, and almost twofold compared with the odds for patients receiving 150 mg bupropion SR (sustained release) twice daily. In these two trials where patients were randomized to either varenicline or bupropion, the efficacy of varenicline was consistently superior at 12 weeks; this result sustained significance at 24 weeks in both studies and up to 52 weeks in one study. Nausea, a common adverse event reported in clinical trials, led to few treatment discontinuations. Its targeted mechanism of action, superior efficacy and excellent tolerability make varenicline a welcome and useful addition to the therapeutic options for smoking cessation. En ligne : https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_ [...] Format de la ressource électronique : PDF, HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7932 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline / Gillian M. Keating (2006)
Titre : Varenicline : a review of its use as an aid to smoking cessation therapy Type de document : texte imprimé Auteurs : Gillian M. Keating, Auteur ; Asif A. Siddiqui, Auteur Editeur : Adis International Année de publication : 2006 Collection : CNS Drugs, ISSN 1172-7047 num. Vol 20, n. 11 Importance : p. 945-960 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract
Varenicline is an orally administered alpha4beta2 nicotinic acetylcholine (ACh) receptor partial agonist. It has been approved by the US FDA (Chantix) and the European Commission (Champix) for use as an aid to smoking cessation therapy. Varenicline is an effective and generally well tolerated treatment for use in smokers who want to quit. In two well designed, phase III trials, 12 weeks' treatment with varenicline was associated with significantly higher continuous abstinence rates at weeks 9-12 than placebo or bupropion sustained-release (SR). In the longer term, continuous abstinence rates for weeks 9 through 52 demonstrated that the odds of remaining abstinent were 2.7 to 3.1 times higher with 12 weeks of varenicline treatment than with placebo; the significant difference between varenicline and bupropion SR was also maintained in the longer term in one trial. Moreover, varenicline appeared to attenuate the urge to smoke, negative affect withdrawal symptoms and the reinforcing effects of smoking. Among those achieving abstinence, an additional 12 weeks of varenicline therapy helped increase the likelihood of long-term abstinence. Thus, varenicline is a valuable new agent for use as an aid to smoking cessation treatment.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7942 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005483 TA 6.2.3.1.4 KEA V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !